MedPath

Mitometh

Generic Name
Mitometh
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C15H12Cl4
CAS Number
107465-03-2
Unique Ingredient Identifier
H8MTN7XVC2
Background

Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others. Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.

Associated Conditions
-
Associated Therapies
-

Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids

The study involved 55 ESCC patient samples for PDO generation, achieving a 62% culture success rate. ESCOs replicated original tumor histology and were used for drug assays, showing varied responses to chemotherapeutics. PDOs' drug sensitivity correlated with clinical outcomes, indicating their potential in personalized oncology.
© Copyright 2025. All Rights Reserved by MedPath